三基因结核分枝杆菌宿主反应检测卡使用指尖血诊断儿童结核病的诊断准确性:低收入和中等收入国家的多中心前瞻性研究
RaPaed-TB是一项在非洲四国和印度开展的前瞻性诊断准确性研究,评估Cepheid结核分枝杆菌宿主反应检测卡(MTB-HR)使用指尖血检测三基因转录组特征对15岁以下疑似结核病儿童的诊断价值。639名有诊断分类的儿童纳入分析,对培养确诊结核的敏感性为59.8%(95%CI 50.8-68.4),三种参考标准下特异性均为90.3%(95%CI 85.5-94.0)。
要点
- MTB-HR对培养确诊结核敏感性59.8%(95%CI 50.8-68.4),特异性90.3%(95%CI 85.5-94.0)。
- 采用任何微生物学确诊时敏感性41.6%(95%CI 34.7-48.7),采用复合临床参考标准时敏感性29.6%(95%CI 25.4-34.2)。
- 基线MTB-HR联合一次Xpert MTB/RIF Ultra可识别71.2%微生物学确诊结核患儿。
核心结论
- MTB-HR在该大型、地理多样化的儿童队列及难以诊断亚组中,对培养确诊结核显示出有前景的诊断准确性。
研究设计与样本
- RaPaed-TB为前瞻性诊断准确性研究,在马拉维、莫桑比克、南非、坦桑尼亚四国及印度各一中心开展。
- 2019年1月21日至2021年6月30日纳入15岁以下疑似肺结核或肺外结核儿童。
- 5313名可能合格儿童接受筛查,975名合格,784名有MTB-HR检测结果,639名有诊断分类并纳入分析。
- MTB-HR在所有儿童基线和1个月时检测,接受结核治疗的儿童在3个月和6个月时重复检测。
- 准确性对照基于标准化微生物学、影像学和临床数据的结核状态。
主要发现
- MTB-HR区分培养确诊结核与不太可能结核儿童的敏感性为59.8%(95%CI 50.8-68.4)。
- 采用任何微生物学确诊(培养、Xpert MTB/RIF Ultra或两者)时敏感性为41.6%(95%CI 34.7-48.7)。
- 采用复合临床参考标准时敏感性为29.6%(95%CI 25.4-34.2)。
- 三种参考标准下特异性均为90.3%(95%CI 85.5-94.0)。
- 不同年龄组和营养不良状态间表现相似;合并HIV感染儿童对严格参考标准的准确性趋向较低(敏感性50.0%,95%CI 15.7-84.3),非HIV感染儿童为61.0%(95%CI 51.6-69.9),差异未达统计学显著。
局限性
- 合并HIV感染儿童对严格参考标准的准确性趋向较低(敏感性50.0%,95%CI 15.7-84.3),非HIV感染儿童为61.0%(95%CI 51.6-69.9),差异未达统计学显著。
- 采用复合临床参考标准时敏感性为29.6%(95%CI 25.4-34.2)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Childhood tuberculosis remains a major cause of morbidity and mortality in part due to missed diagnosis. Diagnostic methods with enhanced sensitivity using easy-to-obtain specimens are needed. We aimed to assess the diagnostic accuracy of the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), a candidate test measuring a three-gene transcriptomic signature from fingerstick blood, in children with presumptive tuberculosis disease. METHODS: RaPaed-TB was a prospective diagnostic accuracy study conducted at four sites in African countries (Malawi, Mozambique, South Africa, and Tanzania) and one site in India. Children younger than 15 years with presumptive pulmonary or extrapulmonary tuberculosis were enrolled between Jan 21, 2019, and June 30, 2021. MTB-HR was performed at baseline and at 1 month in all children and was repeated at 3 months and 6 months in children on tuberculosis treatment. Accuracy was compared with tuberculosis status based on standardised microbiological, radiological, and clinical data. FINDINGS: 5313 potentially eligible children were screened, of whom 975 were eligible. 784 children had MTB-HR test results, of whom 639 had a diagnostic classification and were included in the analysis. MTB-HR differentiated children with culture-confirmed tuberculosis from those with unlikely tuberculosis with a sensitivity of 59·8% (95% CI 50·8-68·4). Using any microbiological confirmation (culture, Xpert MTB/RIF Ultra, or both), sensitivity was 41·6% (34·7-48·7), and using a composite clinical reference standard, sensitivity was 29·6% (25·4-34·2). Specificity for all three reference standards was 90·3% (95% CI 85·5-94·0). Performance was similar in different age groups and by malnutrition status. Among children living with HIV, accuracy against the strict reference standard tended to be lower (sensitivity 50·0%, 15·7-84·3) compared with those without HIV (61·0%, 51·6-69·9), although the difference did not reach statistical significance. Combining baseline MTB-HR result with one Ultra result identified 71·2% of children with microbiologically confirmed tuberculosis. INTERPRETATION: MTB-HR showed promising diagnostic accuracy for culture-confirmed tuberculosis in this large, geographically diverse, paediatric cohort and hard-to-diagnose subgroups. FUNDING: European and Developing Countries Clinical Trials Partnership, UK Medical Research Council, Swedish International Development Cooperation Agency, Bundesministerium für Bildung und Forschung; German Center for Infection Research (DZIF).
引用
- Olbrich L, Verghese VP, Franckling-Smith Z, et al. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries. Lancet Infect Dis. 2023. PMID: 37918414. doi:10.1016/S1473-3099(23)00491-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。